FUROSEMIDE Oral Solution USP, 40 mg per 5 mL and 10 mg per mL

/FUROSEMIDE Oral Solution USP, 40 mg per 5 mL and 10 mg per mL
FUROSEMIDE Oral Solution USP, 40 mg per 5 mL and 10 mg per mL2018-09-06T09:12:40+00:00

Prescription Drug Name:

FUROSEMIDE Oral Solution USP, 40 mg per 5 mL and 10 mg per mL

ID:

48c01593-bf9c-4a66-9349-508a680d7906

Code:

34391-3

WARNING


id: ca903201-13f7-48de-ba40-2845a25b5d2c
displayName: WARNINGS SECTION
FDA Article Code: 34071-1

Furosemide is a potent diuretic which, if given in excessive amounts, can lead to a profound diuresis with water and electrolyte depletion. Therefore, careful medical supervision is required and dose and dose schedule must be adjusted to the individual patient’s needs. (See DOSAGE AND ADMINISTRATION.)

DESCRIPTION


id: 23c61589-ca9b-4672-889d-5bf70cf8389b
displayName: DESCRIPTION SECTION
FDA Article Code: 34089-3

Each mL of Oral Solution for oral administration contains:

Furosemide 10 mg, or 8 mg (40 mg per 5 mL)
Furosemide is a diuretic which is an anthranilic acid derivative. Chemically, it is 4-chloro-N-furfuryl-5-sulfamoylanthranilic acid. Furosemide is a white to off-white, odorless, crystalline powder. It is practically insoluble in water, sparingly soluble in alcohol, freely soluble in dilute alkali solutions and insoluble in dilute acids. The CAS Registry Number is 54-31-9. The structural formula is as follows:

C12H11CIN2O5S                  M.W. 330.74           

Furosemide Oral Solution is available in two strengths: 40 mg per 5 mL, and 10 mg per mL.

CLINICAL PHARMACOLOGY


id: 1b778e07-c98d-4f2a-bc19-c47159870e4f
displayName: CLINICAL PHARMACOLOGY SECTION
FDA Article Code: 34090-1

Investigations into the mode of action of furosemide have utilized micropuncture studies in rats, stop flow experiments in dogs and various clearance studies in both humans and experimental animals. It has been demonstrated that furosemide inhibits primarily the absorption of sodium and chloride not only in the proximal and distal tubules but also in the loop of Henle. The high degree of efficacy is largely due to the unique site of action. The action on the distal tubule is independent of any inhibitory effect on carbonic anhydrase and aldosterone. Recent evidence suggests that furosemide glucuronide is the only or at least the major biotransformation product of furosemide in man. Furosemide is extensively bound to plasma proteins, mainly to albumin. Plasma concentrations ranging from 1 to 400 μg/mL are 91 to 99% bound in healthy individuals. The unbound fraction averages 2.3 to 4.1% at therapeutic concentrations. The onset of diuresis following oral administration is within 1 hour. The peak effect occurs within the first or second hour. The duration of diuretic effect is 6 to 8 hours. In fasted normal men, the mean bioavailability of furosemide from Furosemide Tablets and Furosemide Oral Solution is 64% and 60%, respectively, of that from an intravenous injection of the drug. Although furosemide is more rapidly absorbed from the oral solution (50 minutes) than from the tablet (87 minutes), peak plasma levels and area under the plasma concentration-time curves do not differ significantly. Peak plasma concentrations increase with increasing dose but times-to-peak do not differ among doses. The terminal half-life of furosemide is approximately 2 hours. Significantly more furosemide is excreted in urine following the IV injection than after the tablet or oral solution. There are no significant differences between the two oral formulations in the amount of unchanged drug excreted in urine.

CONTRAINDICATIONS


id: 55183e48-a43a-4766-a8bf-e6a6fdd18c82
displayName: CONTRAINDICATIONS SECTION
FDA Article Code: 34070-3

Furosemide is contraindicated in patients with anuria and in patients with a history of hypersensitivity to furosemide.

WARNINGS


id: 80ffccb9-5443-4ce0-8d79-e0776c9df9f9
displayName: WARNINGS SECTION
FDA Article Code: 34071-1

In patients with hepatic cirrhosis and ascites, furosemide therapy is best initiated in the hospital. In hepatic coma and in states of electrolyte depletion, therapy should not be instituted until the basic condition is improved. Sudden alterations of fluid and electrolyte balance in patients with cirrhosis may precipitate hepatic coma; therefore, strict obsevation is necessary during the period of diuresis. Supplemental potassium chloride and, if required, an aldosterone antagonist are helpful in preventing hypokalemia and metabolic alkalosis. If increasing azotemia and oliguria occur during treatment of severe progressive renal disease, furosemide should be discontinued. Cases of tinnitus and reversible or irreversible hearing impairment and deafness have been reported. Reports usually indicate that furosemide ototoxicity is associated with rapid injection, severe renal impairment, the use of higher than recommended doses, hypoproteinemia or concomitant therapy with aminoglycoside antibiotics, ethacrynic acid, or other ototoxic drugs. If the physician elects to use high dose parenteral therapy, controlled intravenous infusion is advisable (for adults, an infusion rate not exceeding 4 mg furosemide per minute has been used). (See PRECAUTIONS: Drug Interactions .)

ADVERSE REACTIONS


id: 236ab5cf-3492-49b0-8957-e90a22c50811
displayName: ADVERSE REACTIONS SECTION
FDA Article Code: 34084-4

Adverse reactions are categorized below by organ system and listed by decreasing severity.

OVERDOSAGE


id: 9b4b1d62-b763-474b-907d-c819ffa19b99
displayName: OVERDOSAGE SECTION
FDA Article Code: 34088-5

The principal signs and symptoms of overdose with furosemide are dehydration, blood volume reduction, hypotension, electrolyte imbalance, hypokalemia and hypochloremic alkalosis, and are extensions of its diuretic action. The acute toxicity of furosemide has been determined in mice, rats and dogs. In all three, the oral LD50 exceeded 1000 mg/kg body weight, while the intravenous LD50 ranged from 300 to 680 mg/kg. The acute intragastric toxicity in neonatal rats is 7 to 10 times that of adult rats. The concentration of furosemide in biological fluids associated with toxicity or death is not known. Treatment of overdosage is supportive and consists of replacement of excessive fluid and electrolyte losses. Serum electrolytes, carbon dioxide level and blood pressure should be determined frequently. Adequate drainage must be assured in patients with urinary bladder outlet obstruction (such as prostatic hypertrophy). Hemodialysis does not accelerate furosemide elimination.

HOW SUPPLIED


id: d1668168-1a53-42aa-9fd2-e073d173e353
displayName: HOW SUPPLIED SECTION
FDA Article Code: 34069-5

Furosemide Oral Solution USP
10 mg per mL Oral Solution
(orange flavored, orange-colored)

NDC 68094-756-62
4 mL per unit dose cup
Thirty (30) cups per shipper Furosemide Oral Solution USP
40 mg per 5 mL Oral Solution
(pineapple-peach flavored, orange-colored)

NDC 68094-867-62
5 mL per unit dose cup
Thirty (30) cups per shipper

PRINCIPAL DISPLAY PANEL – 4 mL Cup Lid


id: 59982181-a3b7-41a6-9a67-36d95104ea7a
displayName: PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
FDA Article Code: 51945-4

NDC 68094-756-59
PrecisionDose™
FUROSEMIDE
Oral Solution USP
40 mg/4 mL
Pkg: Precision Dose, Inc., S. Beloit, IL 61080